Open AccessConcordance between epidermal growth factor receptor status in primary non-small-cell lung cancer and metastases: a post-mortem study☆
Author(s) -
Stefan Watzka,
Irene Rauscher-Pötsch,
Patrick Nierlich,
Ulrike Setinek,
Wolfgang J. Köstler,
Ulrike Pötschger,
Michael Müller,
Johannes Attems
Publication year - 2010
Publication title -
european journal of cardio-thoracic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 133
eISSN - 1873-734X
pISSN - 1010-7940
DOI - 10.1016/j.ejcts.2010.01.023
Subject(s) - concordance , immunohistochemistry , staining , pathology , epidermal growth factor receptor , lung cancer , medicine , adenocarcinoma , lung , cancer
Epidermal growth factor receptor (EGFR)-targeted therapies are a valid therapeutic option for advanced non-small-cell lung cancer (NSCLC), but unequivocally recognised predictive factors for therapeutic response are lacking. However, intrinsic resistance might occur due to loss of EGFR expression during the course of the disease or its treatment.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom